Science’s 2023 Breakthrough of the Year: Weight Loss Drugs with a Real Shot at Fighting Obesity

The STEP-HFpEF study revealed the popular weight loss drug semaglutide — commonly known as Ozempic and Wegovy — is highly effective at treating heart failure in patients with obesity.

This groundbreaking study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named the scientific breakthrough of the year by Science Magazine. 

The results of the STEP-HFpEF study are likely to be a paradigm shift in treating these patients. The study was the leading presentation at the European Society of Cardiology (ESC) 2023 Congress, the largest cardiovascular conference in the world.

Read the full article by Science: Science’s 2023 Breakthrough of the Year: Weight Loss Drugs with a Real Shot at Fighting Obesity

Related Content

Aug. 25, 2023

CNN: Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common Form of Heart Failure, Trial Finds
The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.
Aug. 26, 2023

Good Morning America: New Study Highlights Benefits to Weight Loss Drugs
Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.